2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T662,Lung cancer is the leading cause of cancer-related mortality globally, largely driven by smoking. This study seeks to determine if heavy cannabis use is associated with an increased risk of cancer of the lung and bronchus. This is a retrospective cohort study utilizing 20 years of deidentified electronic medical record data from 67 tertiary healthcare organizations across the United States. Cohorts included adults (≥18 years) diagnosed with cannabis use disorder and a comparison group without cannabis use disorder. Relative risk for development of new cancer of the lung and/or bronchus was analyzed after propensity score matching between groups based on demographics and risk factors for development of lung cancer (n = 149,632 per group). After matching, individuals with cannabis use disorder demonstrated a significantly higher risk of developing lung and/or bronchus cancer compared to those without cannabis use disorder (RR 3.87, 95% CI 3.43-4.38). The risk remained elevated after one and five years of follow-up. A specific increased risk was found for all histologic subtypes analyzed, including small cell carcinoma (RR 2.70, 95% CI 1.31-5.58), adenocarcinoma (RR 2.54, 95% CI 1.59-4.08), and squamous cell carcinoma (RR 2.90, 95% CI 1.41-5.95). These findings suggest that heavy cannabis use is significantly associated with an increased risk of lung cancer. Given the rising prevalence of cannabis use, further research is needed to clarify dose-response relationships and the biological mechanisms driving these associations. Clinicians should consider these risks when advising patients about cannabis use.31:T669,Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment-seeking individuals with CUD. A phase 2, randomized, double-blind, parallel group, placebo-controlled trial was conducted. Two outpatient research clinics in South Carolina, USA, from February 2020 to February 2023. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for CUD and used cannabis a minimum of 3 days per week. One hundred and seventy-four participants were randomized to either varenicline (n = 90) or placebo (n = 84) stratified by smoking status and sex. Varenicline (titrated to goal dose of 1 mg twice daily) or matching placebo for 12 weeks. Medical management was provided weekly. Primary outcome measure was reduction in total number of cannabis use sessions at each weekly visit (weeks 6-12). There was no main effect of treatment on reduction of total number of cannabis use sessions per week during weeks 6 through 12 [between group difference (Δ) = 1.7; 95% confidence interval (CI) = -1.0 to 4.7; P = 0.41]; however, a statistically significant treatment by sex interaction was found (F Varenicline with medical management resulted in decreased cannabis use among men with cannabis use disorder seeking treatment, but not women (no effect was observed on the overall sample of treatment-seeking individuals with cannabis use disorder).32:Tf0e,Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD. Design A phase 2, randomized, double‐blind, parallel group, placebo‐controlled trial was conducted. Setting Two outpatient research clinics in South Carolina, USA, from February 2020 to February 2023. Participants Eligible participants met Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM‐5) criteria for CUD and used cannabis a minimum of 3 days per week. One hundred and seventy‐four participants were randomized to either varenicline ( n = 90) or placebo ( n = 84) stratified by smoking status and sex. Interventions Varenicline (titrated to goal dose of 1 mg twice daily) or matching placebo for 12 weeks. Medical management was provided weekly. Measurements Primary outcome measure was reduction in total number of cannabis use sessions at each weekly visit (weeks 6–12). Findings There was no main effect of treatment on reduction of total number of cannabis use sessions per week during weeks 6 through 12 [between group difference (Δ) = 1.7; 95% confidence interval (CI) = −1.0 to 4.7; P = 0.41]; however, a statistically significant treatment by sex interaction was found (F 1,132 = 5.1; P = 0.026), with a statistically significant effect of varenicline on reduction of cannabis use sessions per week observed in men (Δ = 4.2; 95% CI = 0.6–7.8; P = 0.04) but not women (Δ = −1.4; 95% CI = −5.7 to 3.0; P = 0.18). Conclusions Varenicline with medical management resulted in decreased cannabis use among men with cannabis use disorder seeking treatment, but not women (no effect was observed on the overall sample of treatment‐seeking individuals with cannabis use disorder). 33:T891,Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta-9-tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC). Data from the CannTeen study, a longitudinal observational study consisting of five assessments over a 12-month period. London, UK. Participants were n = 65 adults aged 26-29 (46% female, 70.77% white ethnicity) and n = 85 adolescents aged 16-17 (56% female, 65.48% white ethnicity). All participants reported at least one use of cannabis during the 12-month study period. Mean weekly standard THC units were estimated using the Enhanced Cannabis Timeline Followback, a comprehensive and validated assessment of quantity, frequency and potency of cannabis consumed. This was administered at 3-month intervals and averaged over a 12-month period. Past 12-month diagnosis of CUD using The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was assessed at the final follow-up. Receiver operating characteristic curve models estimated the extent to which weekly standard THC unit consumption could discriminate no CUD from any CUD (mild, moderate or severe), and no CUD from moderate/severe CUD, in adults and adolescents separately. Risk thresholds were selected based on cut-offs that maximised sensitivity and specificity. Discrimination accuracy of weekly standard THC units on CUD was good, with area under the curve > 0.70 for all models. Optimal cut-offs for risk of any CUD (versus no CUD) were 8.26 units per week for adults and 6.04 units per week for adolescents. For risk of moderate/severe CUD (versus no CUD) optimal cut-offs were 13.44 units per week for adults and 6.45 units per week for adolescents. Weekly cannabis consumption based on standard delta-9-tetrahydrocannabinol (THC) units appears to show good discrimination accuracy of cannabis use disorder at different severities and in different age groups. Safer levels of cannabis use, defined by low weekly standard THC unit consumption, could be recommended in lower risk cannabis use guidelines.34:Te33,Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC). Design Data from the CannTeen study, a longitudinal observational study consisting of five assessments over a 12‐month period. Setting London, UK. Participants Participants were n = 65 adults aged 26–29 (46% female, 70.77% white ethnicity) and n = 85 adolescents aged 16–17 (56% female, 65.48% white ethnicity). All participants reported at least one use of cannabis during the 12‐month study period. Measurements Mean weekly standard THC units were estimated using the Enhanced Cannabis Timeline Followback, a comprehensive and validated assessment of quantity, frequency and potency of cannabis consumed. This was administered at 3‐month intervals and averaged over a 12‐month period. Past 12‐month diagnosis of CUD using The Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM‐5) was assessed at the final follow‐up. Receiver operating characteristic curve models estimated the extent to which weekly standard THC unit consumption could discriminate no CUD from any CUD (mild, moderate or severe), and no CUD from moderate/severe CUD, in adults and adolescents separately. Risk thresholds were selected based on cut‐offs that maximised sensitivity and specificity. Findings Discrimination accuracy of weekly standard THC units on CUD was good, with area under the curve > 0.70 for all models. Optimal cut‐offs for risk of any CUD (versus no CUD) were 8.26 units per week for adults and 6.04 units per week for adolescents. For risk of moderate/severe CUD (versus no CUD) optimal cut‐offs were 13.44 units per week for adults and 6.45 units per week for adolescents. Conclusions Weekly cannabis consumption based on standard delta‐9‐tetrahydrocannabinol (THC) units appears to show good discrimination accuracy of cannabis use disorder at different severities and in different age groups. Safer levels of cannabis use, defined by low weekly standard THC unit consumption, could be recommended in lower risk cannabis use guidelines. 35:T5f1,Abstract As more countries explore regulatory models for non-medical cannabis, concerns persist about its mental health impact. While frequent use has been linked to depression and anxiety, the strength and direction of these associations remain uncertain. This study presents baseline data from Züri Can , a longitudinal observational study in Zurich, Switzerland, evaluating cannabis access under a strictly regulated framework. We conducted a cross-sectional analysis of 2207 participants who completed assessments prior to purchasing cannabis. Mental health was assessed using the PHQ-9 and GAD-7, and substance use with the CUDIT-R and AUDIT-C. Despite high cannabis use (56.4% ≥ 4 days/week) and 24.5% meeting criteria for cannabis use disorder, the prevalence of depression (2.8%) and anxiety (1.7%) was lower than in the general population. Mixed-model analyses indicated modest positive associations between cannabis use and symptoms of depression and anxiety, whereas alcohol, other illicit substances, prescription medication, female gender, and lower income showed similar or stronger positive associations. These findings suggest that mental health risks among frequent users may not primarily manifest as mood disorders but as substance use disorders and highlight the value of screening procedures in regulated cannabis frameworks. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Cannabis Use Disorder: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Cannabis Use Disorder (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Cannabis%20Use%20Disorder\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cannabis Use Disorder\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Cannabis%20Use%20Disorder\"}]}}"}}]],["$","$L2f",null,{"title":"Cannabis Use Disorder: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Cannabis Use Disorder with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1111/add.70597","pmid":"42728108","title":"Adolescent cannabis use disorder following recreational cannabis legalization in California, USA: A population‐based interrupted time series study","journal_title":"Addiction","journal_issn":"0965-2140","published_at":"2026-09-11T00:00:00.000Z","url":"https://doi.org/10.1111/add.70597","source_score":37,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-16T06:22:58.063Z","updated_at":"2026-09-16T06:22:58.063Z","tags":[{"paper_doi":"10.1111/add.70597","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"generic","value":"cannabis","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"modality","value":"Cannabis","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"sample_size","value":"n=637461","value_numeric":637461},{"paper_doi":"10.1111/add.70597","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"study_design","value":"Interrupted Time Series Study","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"warning","value":"CUD diagnoses are EHR-based; changes in clinician coding behavior or help-seeking patterns over the study period could confound observed trends.","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"warning","value":"The interrupted time series design can identify associations with legalization timing but cannot fully rule out concurrent secular trends or other policy changes as contributors.","value_numeric":null},{"paper_doi":"10.1111/add.70597","tag_type":"warning","value":"The study population is drawn from a single large integrated health system (Kaiser Permanente Northern California), which may skew toward insured, higher-SES populations — generalizability beyond this group is uncertain.","value_numeric":null}],"summaries":{"what_studied":"This population-based interrupted time series study examined whether recreational cannabis legalization (RCL) in California changed incident cannabis use disorder (CUD) rates among adolescents aged 13–17 enrolled in Kaiser Permanente Northern California (n=637,461), from January 2014 to February 2020, with two key exposure points: RCL passage (November 2016) and retail sales implementation (January 2018).","key_result":"Before RCL passage, CUD rates were declining (aRR=0.95/year, 95% CI 0.92–0.97). Following passage (+6-month lag), rates sharply increased (slope change aRR=1.26, 95% CI 1.14–1.38). After retail implementation (+6 months), the slope attenuated significantly (aRR=0.86, 95% CI 0.76–0.98), but the overall CUD trend remained above pre-legalization levels through the end of follow-up.","limitations":"- Single integrated health system in Northern California limits generalizability to uninsured, publicly insured, or geographically distinct adolescent populations.\n- CUD ascertainment relies on EHR diagnoses, which may undercount cases not presenting for care or not documented clinically.\n- Study period ends February 2020, capturing only ~2 years post-retail implementation, limiting long-term conclusions.","practice_takeaway":"Clinicians should actively screen adolescents for cannabis use disorder, not just use frequency, given that CUD rates rose following legalization even as general-use trends were tracked separately. Public health monitoring of RCL should include disorder-level outcomes, not only prevalence data."}},{"doi":"10.1001/jamapsychiatry.2026.2497","pmid":"42616541","title":"Trends in the Prevalence and Severity of Alcohol and Cannabis Use Disorders Among US Adults","journal_title":"JAMA Psychiatry","journal_issn":"2168-622X","published_at":"2026-08-19T00:00:00.000Z","url":"https://doi.org/10.1001/jamapsychiatry.2026.2497","source_score":34,"is_retracted":false,"is_open_access":null,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":false},"created_at":"2026-08-20T06:47:51.635Z","updated_at":"2026-08-20T06:47:51.635Z","tags":[{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"condition","value":"Alcohol Use Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"sample_size","value":"n=186823","value_numeric":186823},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.2497","tag_type":"warning","value":"The DOI and publication date (2026) are ahead of current real-world literature; content is treated as presented. No interventional comparator exists—this is a prevalence/trend study, so 'level of evidence 3' reflects observational epidemiology rather than a clinical trial. The age-group breakdown in the sample description appears to cover only ~53.7% of participants (18–49 yrs listed), suggesting a large ≥50 yr cohort not explicitly quantified in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Cross-sectional study of 186,823 US adults (2021–2024 NSDUH) examining trends in past-year prevalence and severity (DSM-5) of alcohol use disorder (AUD) and cannabis use disorder (CUD), stratified by age group and sex.","key_result":"Moderate-to-severe CUD prevalence rose in both sexes (males: 3.1%→4.1%, P<.001; females: 1.7%→2.5%, P<.001), with the sharpest increases in older age groups (females ≥50 yrs: 0.1%→0.7%). By contrast, moderate-to-severe AUD prevalence stayed stable across nearly all sex and age subgroups. Among young adults (18–20 yrs) with CUD, 51–61% had moderate-to-severe disorder in 2024.","limitations":"Cross-sectional design precludes causal inference; self-reported cannabis and alcohol use may underestimate true prevalence; survey data cannot capture unhoused or institutionalized populations.","practice_takeaway":"Routine screening for CUD should be expanded across all adult age groups and sexes, especially in older adults where increases were steepest. Clinicians should not assume cannabis carries low addiction risk—most young adults with CUD already meet criteria for moderate-to-severe disorder."}},{"doi":"10.1016/j.biopsych.2026.06.025","pmid":"42610992","title":"Cannabis Use and Age-Related Acceleration of Psychosis Onset: A Meta-Analysis","journal_title":"Biological Psychiatry","journal_issn":"0006-3223","published_at":"2026-08-18T00:00:00.000Z","url":"https://doi.org/10.1016/j.biopsych.2026.06.025","source_score":156,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-23T07:33:00.262Z","updated_at":"2026-08-23T07:33:00.262Z","tags":[{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"category","value":"Neurosciences","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"condition","value":"Psychosis","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"generic","value":"cannabis","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"modality","value":"Cannabis","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"sample_size","value":"n=71073","value_numeric":71073},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"study_design","value":"Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"warning","value":"Sample size reported as combined total of cannabis users (18,272) and nonusers (52,801) = 71,073; individual study-level Ns vary. The <20-year-old subgroup showed no significant AAO difference, which is counterintuitive and may reflect selection or ascertainment bias — clinicians should interpret this subgroup result cautiously.","value_numeric":null},{"paper_doi":"10.1016/j.biopsych.2026.06.025","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied given the large evidence base and clear dose-age gradient, but causality remains unproven due to observational study designs.","value_numeric":null}],"summaries":{"what_studied":"This meta-analysis examined whether cannabis use is associated with an earlier age at onset (AAO) of psychosis, pooling 181 samples from 149 cohort and case-control studies (18,272 cannabis users vs. 52,801 nonusers) identified from MEDLINE, Embase, and PsycInfo through April 2025.","key_result":"Cannabis use was associated with a mean earlier psychosis onset of **2.50 years** overall. The effect grew with later typical onset age: no difference in the <20-year-old group, but 1.60, 4.43, and 6.30 years earlier in the 20–<25, 25–<30, and ≥30 age groups, respectively. Sample mean onset age was a strong independent moderator (z = −7.59, p < .0001).","limitations":"- Relies on cohort and case-control study designs; cannot establish causation.\n- Between-study heterogeneity is expected given the broad range of included samples and methodologies.\n- Cannabis potency and frequency of use data were not uniformly reported across studies, limiting dose-response analysis.","practice_takeaway":"Clinicians should counsel patients—especially adults over 20—that cannabis use is linked to meaningfully earlier psychosis onset, with the gap widening substantially in older age groups. Public health messaging about cannabis and psychiatric risk should not be limited to adolescents."}},{"doi":"10.1016/j.addbeh.2026.108829","pmid":"42612527","title":"Cannabis use modalities are associated with sociodemographic characteristics and patterns of cannabis use among US adults: A latent class analysis","journal_title":"Addictive Behaviors","journal_issn":"0306-4603","published_at":"2026-08-08T00:00:00.000Z","url":"https://doi.org/10.1016/j.addbeh.2026.108829","source_score":57,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-21T06:28:06.354Z","updated_at":"2026-08-21T06:28:06.354Z","tags":[{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"condition","value":"Cannabis Use","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"modality","value":"Cannabis Edibles","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"modality","value":"Cannabis Smoking","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"modality","value":"Cannabis Vaping","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"sample_size","value":"n=17732","value_numeric":17732},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"warning","value":"CUD severity direction of effect is noted in the abstract but specific aRRR values for CUD by class (beyond directional statements) were not provided in the available text.","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"warning","value":"Latent class analysis assigns probabilistic class membership; individuals are classified by highest posterior probability, which may misclassify some mixed-modality users.","value_numeric":null},{"paper_doi":"10.1016/j.addbeh.2026.108829","tag_type":"warning","value":"The level of evidence is assigned as 3 (cross-sectional/observational) rather than a lower tier because the large, nationally representative sample and adjusted regression strengthen reliability, though causality cannot be established.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional study used latent class analysis (LCA) on 17,732 US adults reporting past 30-day cannabis use from the 2022–2023 National Survey on Drug Use and Health (NSDUH) to identify patterns of cannabis consumption modality (smoking, vaping, edibles, polymodal) and their associations with demographics, use frequency, and cannabis use disorder (CUD).","key_result":"Four modality classes emerged: primary smoking (48.2%), smoking and vaping (20.5%), mainly edibles (16.9%), and polymodal use (14.4%). Adults aged 18–25 were more likely to be polymodal users (aRRR = 3.58, 95% CI: 2.48–5.18) vs. those ≥50; females favored edibles (aRRR = 1.78, 95% CI: 1.48–2.13). Polymodal users had the highest daily use risk (aRRR = 2.67) and elevated CUD risk; edible-only users had lower daily use (aRRR = 0.49) and lower CUD risk compared to primary smokers.","limitations":"Cross-sectional design prevents causal inference. Self-reported modality data may undercount stigmatized routes. The survey may not fully capture emerging modalities (e.g., dabbing, tinctures).","practice_takeaway":"Clinicians should ask about *how* patients use cannabis, not just whether they use it — polymodal and combined smoking/vaping patterns are linked to higher CUD risk, especially in younger adults. Edible-predominant users may need different harm-reduction messaging than smokers or vapers."}},{"doi":"10.3238/arztebl.m2026.0123","pmid":"42345138","title":"Increase in cannabis-specific hospital admissions after partial legalization in Germany: A nationwide time-series analysis","journal_title":"Deutsches Ärzteblatt international","journal_issn":"1866-0452","published_at":"2026-07-24T00:00:00.000Z","url":"https://doi.org/10.3238/arztebl.m2026.0123","source_score":403,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-25T13:58:00.405Z","updated_at":"2026-07-25T13:58:00.405Z","tags":[{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"condition","value":"Cannabis-Induced Psychosis","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"condition","value":"Cannabis Intoxication","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"generic","value":"cannabis","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"modality","value":"Cannabis","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"study_design","value":"Time-Series Analysis","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"warning","value":"Sample size (total N) was not explicitly reported in the abstract or results; the tag has been omitted accordingly.","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"warning","value":"The abstract notes the rise 'may be' due to high-potency medical cannabis—this is speculative and not directly measured in the study.","value_numeric":null},{"paper_doi":"10.3238/arztebl.m2026.0123","tag_type":"warning","value":"The study covers Germany's specific legal context (April 2024 partial legalization); generalizability to other jurisdictions with different regulatory frameworks may be limited.","value_numeric":null}],"summaries":{"what_studied":"This nationwide time-series analysis examined whether cannabis-specific hospital admission rates in Germany changed after partial legalization on 1 April 2024, tracking weekly inpatient data from January 2022 to September 2025 for both minors and adults, with primary outcomes including all cannabis-specific ICD-10 diagnoses (F12.0–F12.9; T40.7) and secondary outcomes of acute intoxication/poisoning and cannabis-induced psychosis.","key_result":"After legalization, overall cannabis-specific admissions rose immediately by 5.6% (RR = 1.056); among adults, acute cannabis poisoning jumped 37.1% (RR = 1.371) and cannabis-induced psychosis rose 16.4% (RR = 1.164); among minors, an initial 14.9% rise (RR = 1.149) was followed by a gradual weekly decline of 0.4% (RR = 0.996 per week).","limitations":"- Causality cannot be confirmed; the study identifies association only, not mechanism.\n- The rise may partly reflect increased use of newly liberalized **medical** cannabis (higher potency), rather than recreational use alone.\n- Administrative DRG/PEPP data may have coding inconsistencies or lag, and the observation window post-legalization (~18 months) is relatively short.","practice_takeaway":"Clinicians should be alert to increased presentations of acute cannabis intoxication and cannabis-induced psychosis following Germany's 2024 legalization—especially in adults—and should screen for high-potency cannabis use (including medical cannabis) in these patients."}},{"doi":"10.3389/fpsyt.2026.1824748","pmid":null,"title":"Cannabis, psychosis, and violence: case reports and comprehensive evidence review","journal_title":"Frontiers in Psychiatry","journal_issn":"1664-0640","published_at":"2026-07-21T00:00:00.000Z","url":"https://doi.org/10.3389/fpsyt.2026.1824748","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-29T13:31:19.309Z","updated_at":"2026-07-29T13:31:19.309Z","tags":[{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"condition","value":"Cannabis-Induced Psychosis","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"condition","value":"Psychotic Disorder","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"condition","value":"Schizophrenia","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"generic","value":"delta-9-tetrahydrocannabinol","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"modality","value":"Cannabis / THC","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"study_design","value":"Perspective / Narrative Review with Case Series","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"warning","value":"Funding was provided by Drug Free America Foundation, an advocacy organization with a stated anti-cannabis stance, which may introduce bias in framing and case selection.","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"warning","value":"Level of evidence is assigned as 5 (expert opinion/narrative review); the cited primary studies referenced within vary widely in design and quality.","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"warning","value":"Study design is a perspective/narrative review with media-identified case reports — not a systematic review or controlled study. Evidence on violence causality is correlational only; the authors explicitly acknowledge causality cannot be determined.","value_numeric":null},{"paper_doi":"10.3389/fpsyt.2026.1824748","tag_type":"warning","value":"The neurobiological mechanisms discussed (e.g., dendritic spine pruning) are largely based on animal models with limited direct human evidence, as noted by the authors.","value_numeric":null}],"summaries":{"what_studied":"This perspective paper reviews the association between cannabis use (especially high-potency THC products), psychosis, and violent behavior, combining media-identified case reports of cannabis-associated violence with a comprehensive narrative review of epidemiological, neurobiological, and clinical evidence.","key_result":"Cannabis-induced psychosis converts to schizophrenia in 34–47% of cases — the highest rate among all substance-induced psychoses. Adolescents (ages 12–19) using cannabis face an 11.2-fold increased risk of psychotic disorders, rising to 26.7-fold for severe outcomes. Daily use of high-potency cannabis (>10% THC) is associated with a 5-fold higher risk of psychotic disorder. Post-legalization in Canada, ED visits for cannabis-induced psychosis rose ~40%. Among recently discharged psychiatric patients, persistent cannabis users were 2.44 times more likely to be violent than non-users.","limitations":"- Case reports are drawn from mainstream media, not a systematic review of all violent events, introducing major selection bias with no denominator or controls.\n- Causality cannot be established from observational data; reverse causation and shared genetic/environmental confounders are not ruled out.\n- THC toxicology is inconsistently performed or legally withheld across U.S. jurisdictions, leading to significant under-ascertainment of cannabis involvement in violent deaths.","practice_takeaway":"Screen all patients — especially adolescents, young adults, and those with psychiatric disorders — for cannabis use and educate them about the elevated psychosis risk tied to high-potency products. Clinicians should provide long-term follow-up after any cannabis-induced psychosis episode given the high rate of conversion to schizophrenia, and consider second-generation antipsychotics plus behavioral interventions (motivational interviewing, CBT) to support cessation."}},{"doi":"10.1016/j.jaac.2026.06.012","pmid":"42331312","title":"Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis Use Disorder in Early-Onset Psychosis","journal_title":"Journal of the American Academy of Child & Adolescent Psychiatry","journal_issn":"0890-8567","published_at":"2026-06-22T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaac.2026.06.012","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-24T13:21:32.991Z","updated_at":"2026-06-24T13:21:32.991Z","tags":[{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"condition","value":"Early-Onset Psychosis","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"generic","value":"cannabis","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"modality","value":"Substance Use Screening","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"sample_size","value":"n=3473","value_numeric":3473},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"warning","value":"GRADE certainty was low to moderate — conclusions about clinical impact are based on observational data and narrative synthesis, not RCTs.","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"warning","value":"The meta-regression findings are associative, not causal; directionality between CU and negative symptom severity cannot be established from this study design.","value_numeric":null},{"paper_doi":"10.1016/j.jaac.2026.06.012","tag_type":"warning","value":"The wide confidence intervals for current CU (18.5–51.2%) and lifetime CUD (18.2–59.9%) reflect substantial between-study heterogeneity; pooled prevalence estimates should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"This PRISMA-compliant systematic review and meta-analysis examined the prevalence, correlates, and clinical impact of cannabis use (CU) and cannabis use disorder (CUD) in early-onset psychosis (EOP; onset <18 years), searching six databases through July 2025 across 40 studies (N=3,473; mean age 16.2±1.6 years; 59% male).","key_result":"Pooled prevalence in EOP was 32.8% for current CU (95% CI 18.5–51.2%), 40.2% for lifetime CU (95% CI 31.3–49.7%), and 36.6% for lifetime CUD (95% CI 18.2–59.9%). Current CU was associated with male sex, higher hospitalization rates, less severe negative symptoms, and lower odds of a schizophrenia diagnosis; CU commonly preceded psychosis onset and was linked to longer duration of untreated psychosis.","limitations":"- Study quality was mostly fair (67.5% of studies) with GRADE certainty only low to moderate.\n- Wide confidence intervals (especially for current CU and lifetime CUD) suggest substantial heterogeneity across studies.\n- No randomized controlled trials were available to assess intervention efficacy; evidence base is largely observational.","practice_takeaway":"Roughly one-third of youth with early-onset psychosis currently use cannabis and over one-third meet criteria for CUD — screen for cannabis use routinely in this population. Integrate substance use care into early psychosis programs, and prioritize longitudinal and interventional research to guide treatment."}},{"doi":"10.1038/s41386-026-02444-9","pmid":"42230967","title":"The role of subcortical brain tissue iron as an indicator of dopamine neurophysiology in adolescent cannabis use","journal_title":"Neuropsychopharmacology","journal_issn":"0893-133X","published_at":"2026-06-02T00:00:00.000Z","url":"https://doi.org/10.1038/s41386-026-02444-9","source_score":34,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-11T13:42:49.853Z","updated_at":"2026-06-11T13:42:49.853Z","tags":[{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"category","value":"Neurosciences","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"condition","value":"Adolescent Cannabis Use","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"modality","value":"Neuroimaging (MRI/fMRI)","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"sample_size","value":"n=81","value_numeric":81},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"warning","value":"Effect sizes (b=−0.01) are consistent across all CU metrics, which may suggest a floor effect or limited dynamic range in the 1/nT2* measure—clinical magnitude is unclear.","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"warning","value":"The 1/nT2* method is experimental and not yet validated against gold-standard dopamine measures (e.g., PET) in adolescent populations.","value_numeric":null},{"paper_doi":"10.1038/s41386-026-02444-9","tag_type":"warning","value":"The sample is 64.2% female, which is atypical for substance use studies; sex-stratified analyses were not reported, limiting generalizability across sexes.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional MRI study examined whether cannabis use (CU) quantity, frequency, and problem severity in adolescents (n=81, ages 14–17) were associated with subcortical tissue iron—measured via 1/nT2* from resting-state fMRI—as a non-invasive proxy for dopamine neurophysiology.","key_result":"Lower subcortical tissue iron (1/nT2*) was independently linked to more daily concentrate hits (b=−0.01, p<0.001), more hours high (b=−0.01, p=0.016), higher CU frequency (b=−0.01, p=0.01), and greater cannabis use disorder severity (b=−0.01, p=0.003); post-hoc analyses identified the ventral tegmental area (VTA) as the key region.","limitations":"- Cross-sectional design prevents causal inference (pre-existing iron differences cannot be ruled out).\n- Small sample (n=81) with restricted age range (14–17), limiting generalizability.\n- Alcohol and nicotine use were limited but not fully excluded, and other confounders (e.g., sleep, diet) affecting iron levels were not controlled.","practice_takeaway":"Adolescent cannabis use—especially concentrates and frequent use—is tied to reduced dopamine-related brain iron in the VTA, suggesting neurobiological changes that may underlie cannabis use disorder development. Clinicians counseling adolescents should be aware that even early, moderate use patterns appear associated with measurable neurophysiological alterations."}},{"doi":"10.1080/00952990.2026.2650344","pmid":"42048539","title":"Sex differences in age-related patterns of cannabis use disorder symptoms and mental health","journal_title":"The American Journal of Drug and Alcohol Abuse","journal_issn":"0095-2990","published_at":"2026-04-28T00:00:00.000Z","url":"https://doi.org/10.1080/00952990.2026.2650344","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:50:31.546Z","updated_at":"2026-05-07T22:50:31.546Z","tags":[{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"condition","value":"Mental Health Disorders","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"modality","value":"Cannabis","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"sample_size","value":"n=107","value_numeric":107},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"warning","value":"Age range spans 'adult' and 'older adult' categories; results may not apply uniformly across this range.","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"warning","value":"Sample size (n=107) is small for moderation analyses; effect estimates may be unstable.","value_numeric":null},{"paper_doi":"10.1080/00952990.2026.2650344","tag_type":"warning","value":"The wide Bayesian credible intervals for the medical-only vs. recreational/hybrid use sensitivity analysis suggest those findings are exploratory and should not be over-interpreted.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional study examined how age and biological sex jointly influence cannabis use disorder (CUD) symptom severity, mental health, memory, physical health, and sleep quality in 107 middle-aged and older adults (ages 35–78, 54 female) who use cannabis, controlling for years of use.","key_result":"A significant age × sex interaction was found: in females, CUD symptom severity decreased with age (b = −0.20, p = .03) and mental health scores improved (b = 0.59, p = .04); no such age-related effects were seen in males. Medical-only users may show a steeper age-related decline in CUD severity than recreational or hybrid users, though credible intervals were wide.","limitations":"Small sample (n = 107) limits statistical power and generalizability; cross-sectional design prevents causal inference; self-reported biological sex and cannabis use behaviors introduce measurement bias.","practice_takeaway":"When assessing cannabis risk in middle-aged and older patients, consider both sex and reason for use — older females and medical-only users may carry lower CUD risk. Individualized screening rather than a one-size-fits-all approach appears warranted."}},{"doi":"10.1016/j.lungcan.2026.109421","pmid":"42044619","title":"Association of cannabis use and lung cancer: a retrospective cohort study","journal_title":"Lung Cancer","journal_issn":"0169-5002","published_at":"2026-04-28T00:00:00.000Z","url":"https://doi.org/10.1016/j.lungcan.2026.109421","source_score":77,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-04-26","doi":"10.1016/j.lungcan.2026.109421","days":"30","issn":"0169-5002","rank":"2","field":"Clinical Medicine","score":"77","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":{"doi":"10.1016/j.lungcan.2026.109421","title":"Association of cannabis use and lung cancer: a retrospective cohort study.","journal":"Lung cancer (Amsterdam, Netherlands)","methods":"","results":"After matching, individuals with cannabis use disorder demonstrated a significantly higher risk of developing lung and/or bronchus cancer compared to those without cannabis use disorder (RR 3.87, 95% CI 3.43-4.38). The risk remained elevated after one and five years of follow-up. A specific increased risk was found for all histologic subtypes analyzed, including small cell carcinoma (RR 2.70, 95% CI 1.31-5.58), adenocarcinoma (RR 2.54, 95% CI 1.59-4.08), and squamous cell carcinoma (RR 2.90, 95% CI 1.41-5.95).","abstract":"$30","keywords":["Cannabis","Epidemiology","Lung Cancer"],"pubmed_id":"42044619","conclusions":"These findings suggest that heavy cannabis use is significantly associated with an increased risk of lung cancer. Given the rising prevalence of cannabis use, further research is needed to clarify dose-response relationships and the biological mechanisms driving these associations. Clinicians should consider these risks when advising patients about cannabis use.","publication_date":"2026-04-28T00:00:00"},"crossref":{"DOI":"10.1016/j.lungcan.2026.109421","URL":"https://doi.org/10.1016/j.lungcan.2026.109421","ISSN":["0169-5002"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0169500226004824?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0169500226004824?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"109421","type":"journal-article","issue":null,"score":1,"title":["Association of cannabis use and lung cancer: a retrospective cohort study"],"author":[{"given":"Tyler J.","family":"Gallagher","sequence":"first","affiliation":[]},{"given":"Niels C.","family":"Kokot","sequence":"additional","affiliation":[]},{"given":"Joshua","family":"Lopez","sequence":"additional","affiliation":[]},{"given":"Eddie","family":"Rodriguez","sequence":"additional","affiliation":[]},{"given":"Brooks V.","family":"Udelsman","sequence":"additional","affiliation":[]},{"given":"Sean C.","family":"Wightman","sequence":"additional","affiliation":[]},{"given":"Scott M.","family":"Atay","sequence":"additional","affiliation":[]},{"given":"Takashi","family":"Harano","sequence":"additional","affiliation":[]},{"given":"Graeme M.","family":"Rosenberg","sequence":"additional","affiliation":[]},{"given":"Jorge J.","family":"Nieva","sequence":"additional","affiliation":[]},{"given":"Anthony W.","family":"Kim","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,6]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"216","created":{"date-time":"2026-04-22T15:59:59Z","timestamp":1776873599000,"date-parts":[[2026,4,22]]},"indexed":{"date-time":"2026-05-07T21:11:52Z","timestamp":1778188312712,"date-parts":[[2026,5,7]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000,"date-parts":[[2026,6,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0169500226004824"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Association of cannabis use and lung cancer: a retrospective cohort study"},{"name":"journaltitle","label":"Journal Title","value":"Lung Cancer"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.lungcan.2026.109421"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2026-05-07T20:44:22Z","timestamp":1778186662000,"date-parts":[[2026,5,7]]},"issn-type":[{"type":"print","value":"0169-5002"}],"published":{"date-parts":[[2026,6]]},"publisher":"Elsevier BV","reference":[{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0005","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"U.S. Cancer Statistics Lung Cancer Stat Bite. Centers for Disease Control and Prevention. Accessed October 15, 2024. https://www.cdc.gov/united-states-cancer-statistics/publications/lung-cancer-stat-bite.html.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0010","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lung cancer statistics. World Cancer Research Fund International. Accessed October 15, 2024. https://www.wcrf.org/cancer-trends/lung-cancer-statistics/.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0015","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lung Cancer Statistics. Centers for Disease Control and Prevention. Accessed October 15, 2024. https://www.cdc.gov/lung-cancer/statistics/index.html#:∼:text=Lung cancer is the third,for both men and women.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.ccm.2011.09.001","key":"10.1016/j.lungcan.2026.109421_b0020","year":"2011","issue":"4","author":"Dela Cruz","volume":"32","first-page":"605","unstructured":null,"article-title":"Lung cancer: epidemiology, etiology, and prevention","journal-title":"Clin. Chest Med.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tox.2003.08.006","key":"10.1016/j.lungcan.2026.109421_b0025","year":"2004","issue":"1","author":"Roemer","volume":"195","first-page":"31","unstructured":null,"article-title":"Chemical composition, cytotoxicity and mutagenicity of smoke from US commercial and reference cigarettes smoked under two sets of machine smoking conditions","journal-title":"Toxicology","doi-asserted-by":"crossref"},{"DOI":"10.3390/ijms23094559","key":"10.1016/j.lungcan.2026.109421_b0030","year":"2022","issue":"9","author":"Li","volume":"23","first-page":null,"unstructured":null,"article-title":"Metabolic activation and DNA interactions of carcinogenic n-nitrosamines to which humans are commonly exposed","journal-title":"Int. J. Mol. Sci.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(05)70024-3","key":"10.1016/j.lungcan.2026.109421_b0035","year":"2005","issue":"1","author":"Hall","volume":"6","first-page":"35","unstructured":null,"article-title":"Cannabinoids and cancer: causation, remediation, and palliation","journal-title":"Lancet Oncol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0040","year":"2021","issue":"1","author":"Connor","volume":"7","first-page":"1","unstructured":null,"article-title":"Cannabis use and cannabis use disorder","journal-title":"Nat Rev Dis Prim.","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0045","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NCSL. State Medical Cannabis Laws. Published 2024. Accessed October 15, 2024. https://www.ncsl.org/health/state-medical-cannabis-laws.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s42238-020-00056-8","key":"10.1016/j.lungcan.2026.109421_b0050","year":"2020","issue":"1","author":"Reid","volume":"2","first-page":null,"unstructured":null,"article-title":"A qualitative review of cannabis stigmas at the twilight of prohibition","journal-title":"J Cannabis Res.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2022.49797","key":"10.1016/j.lungcan.2026.109421_b0055","year":"2023","issue":"1","author":"Bicket","volume":"6","first-page":null,"unstructured":null,"article-title":"Use of cannabis and other pain treatments among adults with chronic pain in US States with medical cannabis programs","journal-title":"JAMA Netw. Open","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.23.02596","key":"10.1016/j.lungcan.2026.109421_b0060","year":"2024","issue":"13","author":"Braun","volume":"42","first-page":"1575","unstructured":null,"article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","journal-title":"J. Clin. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1093/jamiaopen/ooad035","key":"10.1016/j.lungcan.2026.109421_b0065","year":"2023","issue":"2","author":"Palchuk","volume":"6","first-page":null,"unstructured":null,"article-title":"A global federated real-world data and analytics platform for research","journal-title":"JAMIA Open.","doi-asserted-by":"crossref"},{"DOI":"10.1176/appi.books.9780890425787","key":"10.1016/j.lungcan.2026.109421_b0070","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Diagnostic and statistical manual of mental disorders (5th ed., text rev.). Published online 2022. doi:10.1176/appi.books.9780890425787.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaoto.2024.2419","key":"10.1016/j.lungcan.2026.109421_b0075","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Gallagher TJ, Chung RS, Lin ME, Kim I, Kokot NC. Cannabis Use and Head and Neck Cancer. 2024;1:1-8. doi:10.1001/jamaoto.2024.2419.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0080","year":"2024","issue":null,"author":"Doll","volume":null,"first-page":"1","unstructured":null,"article-title":"Exogenous estrogen in the development of head and neck cancer","journal-title":"JAMA Otolaryngol - Head Neck Surg. Published Online","doi-asserted-by":null},{"DOI":"10.1001/jama.1950.02910390001001","key":"10.1016/j.lungcan.2026.109421_b0085","year":"1950","issue":"3","author":"Wynder","volume":"143","first-page":"329","unstructured":null,"article-title":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","journal-title":"JAMA - J Am Med Assoc.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMsa1211127","key":"10.1016/j.lungcan.2026.109421_b0090","year":"2013","issue":"4","author":"Thun","volume":"368","first-page":"351","unstructured":null,"article-title":"50-year trends in smoking-related mortality in the United States","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.21037/tlcr.2018.05.06","key":"10.1016/j.lungcan.2026.109421_b0095","year":"2018","issue":"3","author":"de Groot","volume":"7","first-page":"220","unstructured":null,"article-title":"The epidemiology of lung cancer","journal-title":"Transl Lung Cancer Res.","doi-asserted-by":"crossref"},{"DOI":"10.1177/2045125312457586","key":"10.1016/j.lungcan.2026.109421_b0100","year":"2012","issue":"6","author":"Atakan","volume":"2","first-page":"241","unstructured":null,"article-title":"Cannabis, a complex plant: different compounds and different effects on individuals","journal-title":"Ther. Adv. Psychopharmacol.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.annonc.2021.08.1945","key":"10.1016/j.lungcan.2026.109421_b0105","year":"2021","issue":"5","author":"Aldea","volume":"32","first-page":"S1024","unstructured":null,"article-title":"Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)","journal-title":"Ann. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13277-015-3279-4","key":"10.1016/j.lungcan.2026.109421_b0110","year":"2015","issue":null,"author":"Bhattacharyya","volume":"36","first-page":"6029","unstructured":null,"article-title":"Cannabis smoke can be a major risk factor for early-age laryngeal cancer—a molecular signaling-based approach","journal-title":"Tumor Biol.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0021-9673(00)82720-X","key":"10.1016/j.lungcan.2026.109421_b0115","year":"1982","issue":"1","author":"Novotný","volume":"238","first-page":"141","unstructured":null,"article-title":"Fractionation and capillary gas chromatographic-mass spectrometric characterization of the neutral components in marijuana and tobacco smoke condensates","journal-title":"J. Chromatogr. A","doi-asserted-by":"crossref"},{"DOI":"10.1513/AnnalsATS.201212-127FR","key":"10.1016/j.lungcan.2026.109421_b0120","year":"2013","issue":"3","author":"Tashkin","volume":"10","first-page":"239","unstructured":null,"article-title":"Effects of marijuana smoking on the lung","journal-title":"Ann. Am. Thorac. Soc.","doi-asserted-by":"crossref"},{"DOI":"10.1021/tx700275p","key":"10.1016/j.lungcan.2026.109421_b0125","year":"2008","issue":"2","author":"Moir","volume":"21","first-page":"494","unstructured":null,"article-title":"A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions","journal-title":"Chem. Res. Toxicol.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM198802113180603","key":"10.1016/j.lungcan.2026.109421_b0130","year":"1988","issue":"6","author":"Wu","volume":"318","first-page":null,"unstructured":null,"article-title":"Pulmonary hazards of smoking marijuana as compared with tobacco","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1016/0091-3057(91)90377-E","key":"10.1016/j.lungcan.2026.109421_b0135","year":"1991","issue":"3","author":"Tashkin","volume":"40","first-page":"651","unstructured":null,"article-title":"Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and delta-9-THC","journal-title":"Pharmacol. Biochem. Behav","doi-asserted-by":"crossref"},{"DOI":"10.1586/ers.11.40","key":"10.1016/j.lungcan.2026.109421_b0140","year":"2011","issue":"4","author":"Lee","volume":"5","first-page":"537","unstructured":null,"article-title":"Effects of smoking cannabis on lung function","journal-title":"Expert Rev. Respir. Med.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0145","year":"2012","issue":"2","author":"Rawal","volume":"92","first-page":"26","unstructured":null,"article-title":"Periodontal and oral manifestations of marijuana use","journal-title":"J Tennessee Dent Assoc.","doi-asserted-by":null},{"DOI":"10.1158/1055-9965.EPI-06-0330","key":"10.1016/j.lungcan.2026.109421_b0150","year":"2006","issue":"10","author":"Hashibe","volume":"15","first-page":"1829","unstructured":null,"article-title":"Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study","journal-title":"Cancer Epidemiol. Biomarkers Prev.","doi-asserted-by":"crossref"},{"DOI":"10.1001/archinte.166.13.1359","key":"10.1016/j.lungcan.2026.109421_b0155","year":"2006","issue":"13","author":"Mehra","volume":"166","first-page":"1359","unstructured":null,"article-title":"The association between marijuana smoking and lung cancer: a systematic review","journal-title":"Arch. Intern. Med.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0160","year":"1997","issue":"5","author":"Sidney","volume":"8","first-page":"722","unstructured":null,"article-title":"Marijuana use and cancer incidence","journal-title":"Cancer Causes Control","doi-asserted-by":null},{"DOI":"10.1183/09031936.00065707","key":"10.1016/j.lungcan.2026.109421_b0165","year":"2008","issue":"2","author":"Aldington","volume":"31","first-page":"280","unstructured":null,"article-title":"Cannabis use and risk of lung cancer: a case-control study","journal-title":"Eur. Respir. J.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0170","year":"2013","issue":"10","author":"Callaghan","volume":"24","first-page":"1811","unstructured":null,"article-title":"Marijuana use and risk of lung cancer: a 40-year cohort study","journal-title":"Cancer Causes Control","doi-asserted-by":null},{"DOI":"10.1002/ijc.29036","key":"10.1016/j.lungcan.2026.109421_b0175","year":"2014","issue":"4","author":"Zhang","volume":"136","first-page":"894","unstructured":null,"article-title":"Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium","journal-title":"Int. J. Cancer","doi-asserted-by":"crossref"},{"DOI":"10.15342/ijms.v1i2.57","key":"10.1016/j.lungcan.2026.109421_b0180","year":"2014","issue":"2","author":"Bouti","volume":"1","first-page":"31","unstructured":null,"article-title":"Cannabis smoking and risk of lung cancer - a systematic review and meta-analysis","journal-title":"Int J Med Surg.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s41030-021-00171-8","key":"10.1016/j.lungcan.2026.109421_b0185","year":"2021","issue":"2","author":"Kaplan","volume":"7","first-page":"395","unstructured":null,"article-title":"Cannabis and lung health: does the bad outweigh the good?","journal-title":"Pulm Ther.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.lungcan.2026.109421_b0190","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"LaMotte S. Daily marijuana use linked to increased risk of deadly head and neck cancers, study finds. CNN Health. Published 2024. Accessed November 12, 2024. https://www.cnn.com/2024/08/08/health/marijuana-head-and-neck-cancer-wellness/index.html.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0169-5002(00)00181-1","key":"10.1016/j.lungcan.2026.109421_b0195","year":"2001","issue":"2–3","author":"Khuder","volume":"31","first-page":"139","unstructured":null,"article-title":"Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis","journal-title":"Lung Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1136/tc.2007.022582","key":"10.1016/j.lungcan.2026.109421_b0200","year":"2008","issue":"3","author":"Kenfield","volume":"17","first-page":"198","unstructured":null,"article-title":"Comparison of aspects of smoking among the four histological types of lung cancer","journal-title":"Tob. Control","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0169500226004824"],"article-number":"109421","content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"reference-count":40,"published-online":null,"references-count":40,"special_numbering":"C","short-container-title":["Lung Cancer"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.lungcan.2026.109421","is_oa":false,"title":"Association of cannabis use and lung cancer: a retrospective cohort study","updated":"2026-04-27T08:42:52+00:00","published_date":"2026-04-22","best_oa_location":null}},"created_at":"2026-05-07T22:50:02.095Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"condition","value":"Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"modality","value":"Substance Use / Cannabis","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"sample_size","value":"n=299,264","value_numeric":299264},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"warning","value":"CUD diagnosis codes in EHR data likely underrepresent the full spectrum of heavy cannabis use — results may not generalize to users who are not formally diagnosed.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"warning","value":"The impact_flag 'practice_changing' is tentative; while the findings are striking, the retrospective design and potential residual confounding mean prospective confirmation is warranted before major guideline changes.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109421","tag_type":"warning","value":"Tobacco co-use is a major potential confounder; the abstract does not detail how thoroughly cigarette smoking was accounted for in propensity score matching, which is critical given the high comorbidity between cannabis and tobacco use.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used 20 years of U.S. electronic medical records from 67 tertiary centers to compare lung/bronchus cancer risk in adults with cannabis use disorder (CUD) vs. matched controls without CUD (n=149,632 per group), after propensity score matching for demographics and lung cancer risk factors.","key_result":"CUD was associated with nearly 4× higher risk of lung/bronchus cancer (RR 3.87, 95% CI 3.43–4.38), with elevated risk persisting at 1 and 5 years. All subtypes were affected: squamous cell (RR 2.90), small cell (RR 2.70), and adenocarcinoma (RR 2.54).","limitations":"Residual confounding is a key concern — notably tobacco co-use, which is highly prevalent among cannabis users and may not have been fully captured in EHR data. The study relies on a CUD diagnosis code rather than quantified cannabis exposure, limiting dose-response analysis. Tertiary center data may not be representative of the general population.","practice_takeaway":"Clinicians should counsel patients — especially those with other lung cancer risk factors — that heavy cannabis use (indicated by CUD diagnosis) is associated with significantly elevated lung cancer risk across all major histologic subtypes. Screening discussions should not exclude patients solely because they lack tobacco use history."}},{"doi":"10.1001/jamainternmed.2025.8215","pmid":"41801216","title":"Cannabis and Mental Health","journal_title":"JAMA Internal Medicine","journal_issn":"2168-6106","published_at":"2026-03-09T00:00:00.000Z","url":"https://doi.org/10.1001/jamainternmed.2025.8215","source_score":846,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:49:09.189Z","updated_at":"2026-05-07T22:49:09.189Z","tags":[{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Anxiety Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Attention-Deficit/Hyperactivity Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Bipolar Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Depression","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Posttraumatic Stress Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"condition","value":"Psychotic Disorder","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"generic","value":"cannabidiol","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"generic","value":"delta-9-tetrahydrocannabinol","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"modality","value":"Cannabinoid","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"modality","value":"Cannabis","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"warning","value":"No sample size is applicable as this is a review article, not a primary study.","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"warning","value":"The psychosis risk estimates (2- to 11-fold) span a very wide range, likely reflecting heterogeneous study designs and populations — clinicians should interpret these with caution.","value_numeric":null},{"paper_doi":"10.1001/jamainternmed.2025.8215","tag_type":"warning","value":"This is a narrative review published in JAMA Internal Medicine; it does not report a systematic search strategy or formal risk-of-bias assessment, so the synthesis of evidence may be selective.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the evidence for cannabis use — both THC-predominant products and cannabidiol (CBD) alone — in managing mental health conditions including PTSD, anxiety, depression, ADHD, bipolar disorder, and psychotic disorders, with attention to adverse effects and cannabis use disorder (CUD).","key_result":"Evidence is insufficient or low-certainty for most mental health benefits of cannabis. THC-predominant cannabis may not improve PTSD symptoms (low-certainty), and evidence is largely insufficient for anxiety, depression, and ADHD. CBD alone shows emerging low-certainty benefit for anxiety disorders. Serious harms include: worsening mania in bipolar disorder, increased psychotic symptoms, and CUD in ~3 in 10 past-year users (about half with moderate-to-severe disease). Adolescents and young adults face a 2- to 11-fold increased psychosis risk with high-THC products.","limitations":"Evidence base relies heavily on low-certainty or insufficient studies; long-term effects of THC-predominant cannabis on most mental health conditions remain poorly characterized; review does not detail systematic search methods or risk-of-bias assessments.","practice_takeaway":"Counsel patients — especially adolescents, young adults, and those with bipolar or psychotic disorders — that cannabis carries substantial mental health risks with little proven benefit; cannabis should be avoided in these high-risk groups. Routinely ask patients with mental health conditions about cannabis use, as it is common and likely a modifiable risk factor."}},{"doi":"10.1111/add.70296","pmid":"41536001","title":"Varenicline for cannabis use disorder: A randomized controlled trial","journal_title":"Addiction","journal_issn":"0965-2140","published_at":"2026-01-15T00:00:00.000Z","url":"https://doi.org/10.1111/add.70296","source_score":88,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-19","doi":"10.1111/add.70296","days":"14","issn":"0965-2140","rank":"10","field":"Clinical Medicine","score":"88","category":"Psychiatry","categories":["Psychiatry"],"_categories":["Psychiatry"]},"pubmed":{"doi":"10.1111/add.70296","title":"Varenicline for cannabis use disorder: A randomized controlled trial.","journal":"Addiction (Abingdon, England)","methods":"","results":"","abstract":"$31","keywords":["cannabis","cannabis use disorder","medical management","pharmacotherapy|","sex differences","varenicline"],"pubmed_id":"41536001","conclusions":"","publication_date":"2026-01-15T00:00:00"},"crossref":{"DOI":"10.1111/add.70296","URL":"https://doi.org/10.1111/add.70296","ISSN":["0965-2140","1360-0443"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70296","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/add.70296","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Varenicline for cannabis use disorder: A randomized controlled trial"],"author":[{"given":"Aimee L.","family":"McRae‐Clark","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"},{"name":"Ralph H. Johnson VA Medical Center Charleston SC USA"}]},{"given":"Kevin M.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Nathaniel L.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Brian J.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Bryan","family":"Tolliver","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Jessica","family":"Burt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Alonzo","family":"Steplight","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Elizabeth","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Amanda","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]}],"funder":[{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000002","name":"National Institutes of Health","award":["UH3DA043231"],"award-info":[{"award-number":["UH3DA043231"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,14]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-01-15T05:01:09Z","timestamp":1768453269000,"date-parts":[[2026,1,15]]},"indexed":{"date-time":"2026-01-15T19:46:07Z","timestamp":1768506367509,"date-parts":[[2026,1,15]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000,"date-parts":[[2026,1,14]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000,"date-parts":[[2026,1,14]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/add.70296"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-20"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-11-14"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-14"}],"deposited":{"date-time":"2026-01-15T05:01:14Z","timestamp":1768453274000,"date-parts":[[2026,1,15]]},"issn-type":[{"type":"print","value":"0965-2140"},{"type":"electronic","value":"1360-0443"}],"published":{"date-parts":[[2026,1,14]]},"publisher":"Wiley","reference":[{"DOI":null,"key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Substance Abuse and Mental Health Services Administration.Results from the 2022 National Survey on Drug Use and Health: Detailed tables. Accessed April 10 2024.https://www.samhsa.gov/data/report/2022-nsduh-detailed-tables","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/09540261.2018.1465398","key":"e_1_2_10_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2019.05.008","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/phar.1747","key":"e_1_2_10_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.pharmtox.47.120505.105214","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0306-4522(00)00371-7","key":"e_1_2_10_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1124/mol.106.025130","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1503/cmaj.070256","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.1.47","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.1.56","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euroneuro.2009.11.001","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-014-3518-1","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.biopsych.2009.01.029","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-010-2160-9","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-012-2717-x","key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/ADM.0b013e31829623f4","key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_18_1","year":"2018","issue":null,"author":"O'Malley SS","volume":"75","first-page":"129","unstructured":null,"article-title":"Effect of varenicline combined with medical management on alcohol use disorder: a randomized clinical trial","journal-title":"JAMA","doi-asserted-by":null},{"DOI":"10.1016/j.phrs.2023.106746","key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2021.109111","key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_21_1","year":"1998","issue":"20","author":"Sheehan DV","volume":"59","first-page":"22","unstructured":null,"article-title":"The Mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10","journal-title":"J Clin Psychiatry","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_22_1","year":"1992","issue":null,"author":"Sobell LC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.drugalcdep.2015.08.013","key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2017.04.020","key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2011.06.003","key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1360-0443.2001.967102312.x","key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2011.10111704","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_28_1","year":"2018","issue":null,"author":"Hay RD","volume":"27","first-page":"1185","unstructured":null,"article-title":"PROMIS‐29 v2.0 profile physical and mental health summary scores","journal-title":"Qual Life Res","doi-asserted-by":null},{"DOI":"10.1186/s13293-022-00441-3","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.0006-341X.2001.00120.x","key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/ntr/ntv207","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1037/0893-164X.21.2.216","key":"e_1_2_10_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0740-5472(00)00148-3","key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1037/0022-0167.45.3.265","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/002204260903900310","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/can.2016.0010","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2020.107993","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20230508","key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.161.11.1967","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/add.70296"],"article-number":"add.70296","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Addiction"],"reference-count":38,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,14]]},"references-count":38,"short-container-title":["Addiction"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/add.70296","is_oa":true,"title":"Varenicline for cannabis use disorder: A randomized controlled trial","updated":"2026-01-17T01:14:18+00:00","published_date":"2026-01-14","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70296","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70296","url_for_landing_page":"https://doi.org/10.1111/add.70296"}}},"created_at":"2026-01-21T12:05:26.220Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1111/add.70296","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"generic","value":"varenicline","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"sample_size","value":"n=174","value_numeric":174},{"paper_doi":"10.1111/add.70296","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Details of the treatment-by-sex interaction statistic are truncated in the provided text; exact values by sex were not reported here.","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Only the abstract was available; full methods, adherence, and adverse event data are not included.","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Participant age range was not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A phase 2, randomized, double-blind, placebo-controlled parallel-group trial at two outpatient clinics tested varenicline (titrated to 1 mg twice daily) plus weekly medical management versus placebo for 12 weeks in treatment-seeking individuals meeting DSM-5 criteria for cannabis use disorder (n=174; varenicline n=90, placebo n=84); the primary outcome was reduction in total cannabis use sessions at weekly visits during weeks 6–12.","key_result":"No overall treatment effect on cannabis use sessions during weeks 6–12 (between-group Δ=1.7 sessions/week; 95% CI −1.0 to 4.7; P=0.41); there was a statistically significant treatment-by-sex interaction with decreased use among men but not women.","limitations":"Conducted at two clinics in one U.S. state, which may limit generalizability; benefit was observed only in men despite no overall effect; outcomes were assessed over a 12-week treatment period (primary window weeks 6–12), capturing short-term change only.","practice_takeaway":"Do not expect varenicline plus medical management to reduce cannabis use across all adults with cannabis use disorder; any benefit appears limited to men, with no observed effect in women."}},{"doi":"10.1111/add.70263","pmid":"41521821","title":"Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units","journal_title":"Addiction","journal_issn":"0965-2140","published_at":"2026-01-12T00:00:00.000Z","url":"https://doi.org/10.1111/add.70263","source_score":208,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-14","doi":"10.1111/add.70263","days":"14","issn":"0965-2140","rank":"4","field":"Clinical Medicine","score":"208","category":"Psychiatry","categories":["Psychiatry"],"_categories":["Psychiatry"]},"pubmed":{"doi":"10.1111/add.70263","title":"Estimating thresholds for risk of cannabis use disorder using standard delta-9-tetrahydrocannabinol (THC) units.","journal":"Addiction (Abingdon, England)","methods":"","results":"","abstract":"$33","keywords":["adolescence","cannabis use disorder","harm reduction","lower risk guidelines","risk thresholds","standard THC units"],"pubmed_id":"41521821","conclusions":"","publication_date":"2026-01-12T00:00:00"},"crossref":{"DOI":"10.1111/add.70263","URL":"https://doi.org/10.1111/add.70263","ISSN":["0965-2140","1360-0443"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70263","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/add.70263","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units"],"author":[{"given":"Rachel","family":"Lees Thorne","sequence":"first","affiliation":[{"name":"Addiction and Mental Health Group, Department of Psychology University of Bath Bath UK"}]},{"given":"Will","family":"Lawn","sequence":"additional","affiliation":[{"name":"Department of Psychology King's College London London UK"}]},{"given":"Kat","family":"Petrilli","sequence":"additional","affiliation":[{"name":"Addiction and Mental Health Group, Department of Psychology University of Bath Bath UK"},{"name":"Policy Research Unit King's College London London UK"}]},{"given":"Katie","family":"Trinci","sequence":"additional","affiliation":[{"name":"Clinical Psychopharmacology Unit UCL London UK"}]},{"given":"Anya","family":"Borissova","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK"}]},{"given":"Shelan","family":"Ofori","sequence":"additional","affiliation":[{"name":"Clinical Psychopharmacology Unit UCL London UK"}]},{"given":"Claire","family":"Mokrysz","sequence":"additional","affiliation":[{"name":"Clinical Psychopharmacology Unit UCL London UK"}]},{"given":"H. Valerie","family":"Curran","sequence":"additional","affiliation":[{"name":"Clinical Psychopharmacology Unit UCL London UK"}]},{"given":"Lindsey A.","family":"Hines","sequence":"additional","affiliation":[{"name":"Addiction and Mental Health Group, Department of Psychology University of Bath Bath UK"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Addiction and Mental Health Group, Department of Psychology University of Bath Bath UK"}]}],"funder":[{"id":[{"id":"10.13039/501100000265","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000265","name":"Medical Research Council","award":["MR/N0137941/1"],"award-info":[{"award-number":["MR/N0137941/1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100000265","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000265","name":"Medical Research Council","award":["MR/P012728/1"],"award-info":[{"award-number":["MR/P012728/1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100000265","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000265","name":"Medical Research Council","award":["MR/Y017560/1"],"award-info":[{"award-number":["MR/Y017560/1"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,12]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-01-12T09:00:10Z","timestamp":1768208410000,"date-parts":[[2026,1,12]]},"indexed":{"date-time":"2026-01-13T11:43:09Z","timestamp":1768304589758,"date-parts":[[2026,1,13]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000,"date-parts":[[2026,1,12]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$34","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/add.70263"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-21"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-10-21"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-12"}],"deposited":{"date-time":"2026-01-13T05:26:39Z","timestamp":1768281999000,"date-parts":[[2026,1,13]]},"issn-type":[{"type":"print","value":"0965-2140"},{"type":"electronic","value":"1360-0443"}],"published":{"date-parts":[[2026,1,12]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/j.addbeh.2020.106479","key":"e_1_2_9_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.books.9780890425596","key":"e_1_2_9_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Public Health England.Young people's substance misuse treatment statistics 2021 to 2022: report.2023Feb.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_9_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United Nations.2022World Drug Report 2022","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.drugalcdep.2021.109154","key":"e_1_2_9_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000518648","key":"e_1_2_9_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1465-3362.2011.00313.x","key":"e_1_2_9_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2012.10.015","key":"e_1_2_9_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2022.109582","key":"e_1_2_9_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/add.15253","key":"e_1_2_9_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2020.1035","key":"e_1_2_9_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2215-0366(22)00161-4","key":"e_1_2_9_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2020.108271","key":"e_1_2_9_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000488346","key":"e_1_2_9_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2017.09.035","key":"e_1_2_9_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/add.15702","key":"e_1_2_9_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugpo.2021.103381","key":"e_1_2_9_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.lanepe.2021.100227","key":"e_1_2_9_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2017.03.010","key":"e_1_2_9_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2021.109159","key":"e_1_2_9_21_1","year":"2021","issue":null,"author":"Hasin DS","volume":"229","first-page":null,"unstructured":null,"article-title":"Use of highly‐potent Cannabis concentrate products: More common in U.S. states with recreational or medical Cannabis laws","journal-title":"Drug Alcohol Depend","doi-asserted-by":"crossref"},{"DOI":"10.1111/add.13886","key":"e_1_2_9_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_23_1","year":"2024","issue":null,"author":"Borodovsky JT","volume":null,"first-page":null,"unstructured":null,"article-title":"Quantity of delta‐9‐tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers","journal-title":"Addiction","doi-asserted-by":null},{"DOI":"10.1111/add.14842","key":"e_1_2_9_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cbl.30555","key":"e_1_2_9_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NIDA.Establishing 5mg of THC as the standard unit for research [Internet]. Establishing 5mg of THC as the Standard Unit for Research.2021. Available from:https://nida.nih.gov/about-nida/noras-blog/2021/05/establishing-5mg-thc-standard-unit-research","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1001/jamapsychiatry.2015.1858","key":"e_1_2_9_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_27_1","year":"2022","issue":null,"author":"Lawn W","volume":null,"first-page":null,"unstructured":null,"article-title":"The cannteen study: Cannabis use disorder, depression, anxiety, and psychotic‐like symptoms in adolescent and adult cannabis users and age‐matched controls","journal-title":"J Psychopharmacol (Oxf)","doi-asserted-by":null},{"DOI":"10.3109/00952990.2016.1164711","key":"e_1_2_9_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/add.16460","key":"e_1_2_9_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Office for National Statistics (ONS).ONS.2024Drug misuse in England and Wales: year ending March 2024","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/dta.2368","key":"e_1_2_9_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/add.15381","key":"e_1_2_9_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/add.16405","key":"e_1_2_9_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00406-024-01806-y","key":"e_1_2_9_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugpo.2020.102740","key":"e_1_2_9_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2015.15070907","key":"e_1_2_9_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Office for National Statistics (ONS).Drug misuse in England and Wales: year ending March 2024 [Internet]. [cited 2025 Sept 23]. Available from:https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2024","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/ajad.12186","key":"e_1_2_9_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/add.70263"],"article-number":"add.70263","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Addiction"],"reference-count":37,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,12]]},"references-count":37,"short-container-title":["Addiction"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/add.70263","is_oa":true,"title":"Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units","updated":"2026-01-14T02:41:26+00:00","published_date":"2026-01-12","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70263","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70263","url_for_landing_page":"https://doi.org/10.1111/add.70263"}}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1111/add.70263","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"sample_size","value":"n=150","value_numeric":150},{"paper_doi":"10.1111/add.70263","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"study_design","value":"Cohort","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"warning","value":"Design classified as a cohort study based on the description of a longitudinal observational study.","value_numeric":null},{"paper_doi":"10.1111/add.70263","tag_type":"warning","value":"Only abstract data were available; exact AUC and diagnostic accuracy metrics beyond AUC > 0.70 were not provided.","value_numeric":null}],"summaries":{"what_studied":"CannTeen, a 12‑month longitudinal study in London, assessed whether mean weekly standard THC units (1 unit = 5 mg) predict DSM‑5 cannabis use disorder. It followed 150 cannabis users (65 adults aged 26–29; 85 adolescents aged 16–17) across five assessments and used ROC models to find cut‑offs for any CUD and for moderate/severe CUD by age group.","key_result":"All models showed AUC > 0.70. Optimal weekly cut‑offs were 8.26 units (adults) and 6.04 units (adolescents) for any CUD vs none, and 13.44 units (adults) and 6.45 units (adolescents) for moderate/severe CUD vs none.","limitations":"Small, single‑city UK sample (n=150) with narrow age ranges (16–17 and 26–29) limits generalizability. Exact AUC, sensitivity, and specificity values were not reported in the abstract.","practice_takeaway":"When counseling users, tracking weekly standard THC units may help flag CUD risk: risk thresholds were about 6 units/week in adolescents and 8 units/week in adults for any CUD, with higher adult thresholds for moderate/severe CUD. Apply cautiously given the small, localized sample."}},{"doi":"10.1007/s11469-025-01614-y","pmid":null,"title":"Frequent Non-medical Cannabis Use and Mental Health: A Cross-sectional Analysis Prior to Regulated Access","journal_title":"International Journal of Mental Health and Addiction","journal_issn":"1557-1874","published_at":"2025-12-23T00:00:00.000Z","url":"https://doi.org/10.1007/s11469-025-01614-y","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-24","doi":"10.1007/s11469-025-01614-y","days":"30","issn":"1557-1874","rank":"8","field":"Clinical Medicine","score":"18","category":"Psychology, Clinical","categories":["Psychology, Clinical"],"_categories":["Psychology, Clinical"]},"pubmed":null,"crossref":{"DOI":"10.1007/s11469-025-01614-y","URL":"https://doi.org/10.1007/s11469-025-01614-y","ISSN":["1557-1874","1557-1882"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s11469-025-01614-y.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s11469-025-01614-y","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s11469-025-01614-y.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Frequent Non-medical Cannabis Use and Mental Health: A Cross-sectional Analysis Prior to Regulated Access"],"author":[{"given":"Maximilian","family":"Buschner","sequence":"first","affiliation":[]},{"given":"Nadine","family":"Heckel","sequence":"additional","affiliation":[]},{"given":"Etna J. E.","family":"Engeli","sequence":"additional","affiliation":[]},{"given":"Eva M.","family":"Havelka","sequence":"additional","affiliation":[]},{"given":"Maximilian","family":"Haas","sequence":"additional","affiliation":[]},{"given":"Julia","family":"Wick","sequence":"additional","affiliation":[]},{"given":"Sophie","family":"Schneider","sequence":"additional","affiliation":[]},{"given":"Patricia","family":"Dürler","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Nordt","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"Herdener","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100006447","id-type":"DOI","asserted-by":"crossref"}],"DOI":"10.13039/501100006447","name":"University of Zurich","doi-asserted-by":"crossref"}],"issued":{"date-parts":[[2025,12,23]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2025-12-23T14:32:49Z","timestamp":1766500369000,"date-parts":[[2025,12,23]]},"indexed":{"date-time":"2025-12-23T16:35:03Z","timestamp":1766507703897,"date-parts":[[2025,12,23]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000,"date-parts":[[2025,12,23]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by/4.0","start":{"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000,"date-parts":[[2025,12,23]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$35","language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s11469-025-01614-y"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"18 June 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"4 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"23 December 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"},"order":2,"value":"This study was approved by the Cantonal Ethics Committee Zurich (Kantonale Ethikkommission) and the Swiss Federal Office of Public Health. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study."},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":3,"value":"The authors declare no competing interests."}],"deposited":{"date-time":"2025-12-23T14:32:51Z","timestamp":1766500371000,"date-parts":[[2025,12,23]]},"issn-type":[{"type":"print","value":"1557-1874"},{"type":"electronic","value":"1557-1882"}],"published":{"date-parts":[[2025,12,23]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1016/j.drugalcdep.2010.02.017","key":"1614_CR1","year":"2010","issue":"1–2","author":"SJ Adamson","volume":"110","first-page":"137","unstructured":"Adamson, S. J., Kay-Lambkin, F. J., Baker, A. L., Lewin, T. J., Thornton, L., Kelly, B. J., & Sellman, J. D. (2010). An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug and Alcohol Dependence, 110(1–2), 137–143. https://doi.org/10.1016/j.drugalcdep.2010.02.017","article-title":null,"journal-title":"Drug and Alcohol Dependence","doi-asserted-by":"publisher"},{"DOI":"10.1080/00952990.2019.1674862","key":"1614_CR2","year":"2019","issue":"6","author":"B Adinoff","volume":"45","first-page":"673","unstructured":"Adinoff, B., & Reiman, A. (2019). Implementing social justice in the transition from illicit to legal cannabis. American Journal of Drug and Alcohol Abuse, 45(6), 673–688. https://doi.org/10.1080/00952990.2019.1674862","article-title":null,"journal-title":"American Journal of Drug and Alcohol Abuse","doi-asserted-by":"publisher"},{"DOI":"10.1001/archinte.163.7.821","key":"1614_CR3","year":"2003","issue":"7","author":"KA Bradley","volume":"163","first-page":"821","unstructured":"Bradley, K. A., Bush, K. R., Epler, A. J., Dobie, D. J., Davis, T. M., Sporleder, J. L., Maynard, C., Burman, M. L., & Kivlahan, D. R. (2003). Two brief alcohol-screening tests from the Alcohol Use Disorders Identification Test (AUDIT): Validation in a female veterans affairs patient population. Archives of Internal Medicine, 163(7), 821–829. https://doi.org/10.1001/archinte.163.7.821","article-title":null,"journal-title":"Archives of Internal Medicine","doi-asserted-by":"publisher"},{"DOI":null,"key":"1614_CR4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bundesamt für Statistik BFS. (2023). Schweizerische Gesundheitsbefragung 2022. https://www.bfs.admin.ch/news/en/2023-0115","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.drugpo.2024.104610","key":"1614_CR5","year":"2024","issue":null,"author":"M Buschner","volume":"133","first-page":null,"unstructured":"Buschner, M., Heckel, N., Dürler, P., Engeli, E. J. E., Schneider, S., Havelka, E. M., Nordt, C., & Herdener, M. (2024). The Züri can study: Can regulated cannabis sales promote lower-risk cannabis use? Mini-review and study protocol. International Journal of Drug Policy, 133, Article 104610. https://doi.org/10.1016/j.drugpo.2024.104610","article-title":null,"journal-title":"International Journal of Drug Policy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.econedurev.2014.09.003","key":"1614_CR6","year":"2014","issue":null,"author":"L Crespo","volume":"43","first-page":"36","unstructured":"Crespo, L., López-Noval, B., & Mira, P. (2014). Compulsory schooling, education, depression and memory: New evidence from SHARELIFE. Economics of Education Review, 43, 36–46. https://doi.org/10.1016/j.econedurev.2014.09.003","article-title":null,"journal-title":"Economics of Education Review","doi-asserted-by":"publisher"},{"DOI":"10.1016/s0140-6736(24)00757-8","key":"1614_CR7","year":"2024","issue":"10440","author":"AJ Ferrari","volume":"403","first-page":"2133","unstructured":"Ferrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., ElHafeez, S. A., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., Abdullahi, A., Abegaz, K. H., Zuñiga, R. A. A., Aboagye, R. G., Abolhassani, H., Abreu, L. G., Abualruz, H., Abu-Gharbieh, E., Abu-Rmeileh, N. M., … Murray, C. J. L. (2024). Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet, 403(10440), 2133–2161. https://doi.org/10.1016/s0140-6736(24)00757-8","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugpo.2021.103381","key":"1614_CR8","year":"2022","issue":null,"author":"B Fischer","volume":null,"first-page":null,"unstructured":"Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., van den Brink, W., & Hall, W. (2022). Lower-risk cannabis use guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy. https://doi.org/10.1016/j.drugpo.2021.103381","article-title":null,"journal-title":"International Journal of Drug Policy","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12889-016-3638-0","key":"1614_CR9","year":"2016","issue":"1","author":"A Freeman","volume":"16","first-page":null,"unstructured":"Freeman, A., Tyrovolas, S., Koyanagi, A., Chatterji, S., Leonardi, M., Ayuso-Mateos, J. L., Tobiasz-Adamczyk, B., Koskinen, S., Rummel-Kluge, C., & Haro, J. M. (2016). The role of socio-economic status in depression: Results from the COURAGE (aging survey in Europe). BMC Public Health, 16(1), Article 1098. https://doi.org/10.1186/s12889-016-3638-0","article-title":null,"journal-title":"BMC Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1001/archpsyc.61.8.807","key":"1614_CR10","year":"2004","issue":"8","author":"BF Grant","volume":"61","first-page":"807","unstructured":"Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 61(8), 807–816. https://doi.org/10.1001/archpsyc.61.8.807","article-title":null,"journal-title":"Archives of General Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2022.06.083","key":"1614_CR11","year":"2022","issue":null,"author":"O Hahad","volume":"313","first-page":"100","unstructured":"Hahad, O., Beutel, M., Gilan, D. A., Michal, M., Schulz, A., Pfeiffer, N., König, J., Lackner, K., Wild, P., Daiber, A., & Münzel, T. (2022). The association of smoking and smoking cessation with prevalent and incident symptoms of depression, anxiety, and sleep disturbance in the general population. Journal of Affective Disorders, 313, 100–109. https://doi.org/10.1016/j.jad.2022.06.083","article-title":null,"journal-title":"Journal of Affective Disorders","doi-asserted-by":"publisher"},{"DOI":"10.1111/add.16267","key":"1614_CR12","year":"2023","issue":"9","author":"W Hall","volume":"118","first-page":"1606","unstructured":"Hall, W., & Hoch, E. (2023). Minimizing double standards in assessing the adverse and beneficial effects of cannabis. Addiction, 118(9), 1606–1608. https://doi.org/10.1111/add.16267","article-title":null,"journal-title":"Addiction","doi-asserted-by":"publisher"},{"DOI":"10.1111/add.16274","key":"1614_CR13","year":"2023","issue":"11","author":"W Hall","volume":"118","first-page":"2062","unstructured":"Hall, W., Stjepanović, D., Dawson, D., & Leung, J. (2023). The implementation and public health impacts of cannabis legalization in Canada: A systematic review. Addiction, 118(11), 2062–2072. https://doi.org/10.1111/add.16274","article-title":null,"journal-title":"Addiction","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1360-0443.1989.tb03059.x","key":"1614_CR14","year":"1989","issue":"7","author":"TF Heatherton","volume":"84","first-page":"791","unstructured":"Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., Rickert, W., & Robinson, J. (1989). Measuring the heaviness of smoking: Using self‐reported time to the first cigarette of the day and number of cigarettes smoked per day. British Journal of Addiction, 84(7), 791–800. https://doi.org/10.1111/j.1360-0443.1989.tb03059.x","article-title":null,"journal-title":"British Journal of Addiction","doi-asserted-by":"publisher"},{"DOI":"10.3389/fpsyt.2016.00104","key":"1614_CR15","year":"2016","issue":null,"author":"C Hindocha","volume":"7","first-page":null,"unstructured":"Hindocha, C., Freeman, T. P., Ferris, J. A., Lynskey, M. T., & Winstock, A. R. (2016). No smoke without tobacco: A global overview of cannabis and tobacco routes of administration and their association with intention to quit. Frontiers in Psychiatry, 7, Article 104. https://doi.org/10.3389/fpsyt.2016.00104","article-title":null,"journal-title":"Frontiers in Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1177/20503245221095228","key":"1614_CR16","year":"2022","issue":null,"author":"PG Johnstad","volume":"8","first-page":"205032452210952","unstructured":"Johnstad, P. G. (2022). Comparative harms assessments for cannabis, alcohol, and tobacco: Risk for psychosis, cognitive impairment, and traffic accident. Drug Science, Policy and Law, 8, 20503245221095228. https://doi.org/10.1177/20503245221095228","article-title":null,"journal-title":"Drug Science, Policy and Law","doi-asserted-by":"publisher"},{"DOI":"10.1186/1471-244x-14-136","key":"1614_CR17","year":"2014","issue":"1","author":"KK Kedzior","volume":"14","first-page":null,"unstructured":"Kedzior, K. K., & Laeber, L. T. (2014). A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiatry, 14(1), Article 136. https://doi.org/10.1186/1471-244x-14-136","article-title":null,"journal-title":"BMC Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1001/archpsyc.62.6.617","key":"1614_CR18","year":"2005","issue":"6","author":"RC Kessler","volume":"62","first-page":"617","unstructured":"Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62(6), 617–627. https://doi.org/10.1001/archpsyc.62.6.617","article-title":null,"journal-title":"Archives of General Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1111/add.16644","key":"1614_CR19","year":"2025","issue":"2","author":"B Kilmer","volume":"120","first-page":"209","unstructured":"Kilmer, B. (2025). How psychedelics legalization debates could differ from cannabis. Addiction, 120(2), 209–210. https://doi.org/10.1111/add.16644","article-title":null,"journal-title":"Addiction","doi-asserted-by":"publisher"},{"DOI":"10.1016/s2468-2667(19)30248-8","key":"1614_CR20","year":"2020","issue":"3","author":"M Kivimäki","volume":"5","first-page":"e140","unstructured":"Kivimäki, M., Batty, G. D., Pentti, J., Shipley, M. J., Sipilä, P. N., Nyberg, S. T., Suominen, S. B., Oksanen, T., Stenholm, S., Virtanen, M., Marmot, M. G., Singh-Manoux, A., Brunner, E. J., Lindbohm, J. V., Ferrie, J. E., & Vahtera, J. (2020). Association between socioeconomic status and the development of mental and physical health conditions in adulthood: A multi-cohort study. The Lancet Public Health, 5(3), e140–e149. https://doi.org/10.1016/s2468-2667(19)30248-8","article-title":null,"journal-title":"The Lancet Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/s2215-0366(16)30263-2","key":"1614_CR21","year":"2017","issue":"2","author":"C Kuehner","volume":"4","first-page":"146","unstructured":"Kuehner, C. (2017). Why is depression more common among women than among men? The Lancet Psychiatry, 4(2), 146–158. https://doi.org/10.1016/s2215-0366(16)30263-2","article-title":null,"journal-title":"The Lancet Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1093/eurpub/ckab024","key":"1614_CR22","year":"2021","issue":"4","author":"E Leal-López","volume":"31","first-page":"859","unstructured":"Leal-López, E., Sánchez-Queija, I., Vieno, A., Currie, D., Torsheim, Torbjorn, Pavlova, D., Moreno-Maldonado, C., Clercq, Bart De, Kalman, M., & Inchley, J. (2021). Cross-national time trends in adolescent alcohol use from 2002 to 2014. European Journal of Public Health, 31(4), 859–866. https://doi.org/10.1093/eurpub/ckab024","article-title":null,"journal-title":"European Journal of Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.addbeh.2020.106479","key":"1614_CR23","year":"2020","issue":null,"author":"J Leung","volume":null,"first-page":null,"unstructured":"Leung, J., Chan, G. C. K., Hides, L., & Hall, W. D. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2020.106479","article-title":null,"journal-title":"Addictive Behaviors","doi-asserted-by":"publisher"},{"DOI":"10.1017/s0033291713001438","key":"1614_CR24","year":"2014","issue":null,"author":"S Lev-Ran","volume":"44","first-page":"797","unstructured":"Lev-Ran, S., Roerecke, M., Foll, B. L., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44, 797–810. https://doi.org/10.1017/s0033291713001438","article-title":null,"journal-title":"Psychological Medicine","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2018.10.010","key":"1614_CR25","year":"2019","issue":null,"author":"C Marel","volume":"194","first-page":"136","unstructured":"Marel, C., Sunderland, M., Mills, K. L., Slade, T., Teesson, M., & Chapman, C. (2019). Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug and Alcohol Dependence, 194, 136–142. https://doi.org/10.1016/j.drugalcdep.2018.10.010","article-title":null,"journal-title":"Drug and Alcohol Dependence","doi-asserted-by":"publisher"},{"DOI":"10.1111/eip.12305","key":"1614_CR26","year":"2018","issue":"2","author":"K Maurer","volume":"12","first-page":"217","unstructured":"Maurer, K., Zink, M., Rausch, F., & Häfner, H. (2018). The early recognition inventory ERIraos. Early Intervention in Psychiatry, 12(2), 217–228. https://doi.org/10.1111/eip.12305","article-title":null,"journal-title":"Early Intervention in Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugpo.2019.11.002","key":"1614_CR27","year":"2021","issue":null,"author":"I Obradovic","volume":"91","first-page":null,"unstructured":"Obradovic, I. (2021). From prohibition to regulation: A comparative analysis of the emergence and related outcomes of new legal cannabis policy models (Colorado, Washington State and Uruguay). International Journal of Drug Policy, 91, Article 102590. https://doi.org/10.1016/j.drugpo.2019.11.002","article-title":null,"journal-title":"International Journal of Drug Policy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugpo.2025.104718","key":"1614_CR28","year":"2025","issue":null,"author":"AA Padon","volume":"137","first-page":null,"unstructured":"Padon, A. A., Ghahremani, D. G., Simard, B., Soroosh, A. J., & Silver, L. D. (2025). Characteristics and effects of cannabis advertisements with appeal to youth in California. International Journal of Drug Policy, 137, Article 104718. https://doi.org/10.1016/j.drugpo.2025.104718","article-title":null,"journal-title":"International Journal of Drug Policy","doi-asserted-by":"publisher"},{"DOI":"10.1159/000520178","key":"1614_CR29","year":"2022","issue":"3","author":"BB Quednow","volume":"28","first-page":"186","unstructured":"Quednow, B. B., Steinhoff, A., Bechtiger, L., Ribeaud, D., Eisner, M., & Shanahan, L. (2022). High prevalence and early onsets: Legal and illegal substance use in an urban cohort of young adults in Switzerland. European Addiction Research, 28(3), 186–198. https://doi.org/10.1159/000520178","article-title":null,"journal-title":"European Addiction Research","doi-asserted-by":"publisher"},{"DOI":null,"key":"1614_CR30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Rolles, S., & Slade, H. (2022). How to regulate cannabis: A practical guide (3rd ed.). Transform Drug Policy Foundation.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s40263-024-01148-2","key":"1614_CR31","year":"2025","issue":"2","author":"KA Sagar","volume":"39","first-page":"113","unstructured":"Sagar, K. A., & Gruber, S. A. (2025). The complex relationship between cannabis use and mental health: Considering the influence of cannabis use patterns and individual factors. CNS Drugs, 39(2), 113–125. https://doi.org/10.1007/s40263-024-01148-2","article-title":null,"journal-title":"CNS Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.282.18.1737","key":"1614_CR32","year":"1999","issue":"18","author":"RL Spitzer","volume":"282","first-page":"1737","unstructured":"Spitzer, R. L., Kroenke, K., Williams, J. B. W., Group, and the P. H. Q. P. C. S. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA, 282(18), 1737–1744. https://doi.org/10.1001/jama.282.18.1737","article-title":null,"journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1001/archinte.166.10.1092","key":"1614_CR33","year":"2006","issue":"10","author":"RL Spitzer","volume":"166","first-page":"1092","unstructured":"Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092","article-title":null,"journal-title":"Archives of Internal Medicine","doi-asserted-by":"publisher"},{"DOI":"10.1136/jech-2016-208145","key":"1614_CR34","year":"2017","issue":null,"author":"CD Twomey","volume":"71","first-page":"811","unstructured":"Twomey, C. D. (2017). Association of cannabis use with the development of elevated anxiety symptoms in the general population: A meta-analysis. Journal of Epidemiology and Community Health, 71, 811–816. https://doi.org/10.1136/jech-2016-208145","article-title":null,"journal-title":"Journal of Epidemiology and Community Health","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1360-0443.2002.00185.x","key":"1614_CR35","year":"2002","issue":"9","author":"WHO ASSIST Working Group","volume":"97","first-page":"1183","unstructured":"WHO ASSIST Working Group. (2002). The alcohol, smoking and substance involvement screening test (ASSIST): Development, reliability and feasibility. Addiction, 97(9), 1183–1194. https://doi.org/10.1046/j.1360-0443.2002.00185.x","article-title":null,"journal-title":"Addiction","doi-asserted-by":"publisher"},{"DOI":"10.1177/0706743720952251","key":"1614_CR36","year":"2021","issue":"2","author":"S Xue","volume":"66","first-page":"126","unstructured":"Xue, S., Husain, M. I., Zhao, H., & Ravindran, A. V. (2021). Cannabis use and prospective long-term association with anxiety: A systematic review and meta-analysis of longitudinal studies: Usage du cannabis et association prospective à long terme avec l’anxiété: Une revue systématique et une méta-analyse d’études longitudinales. Canadian Journal of Psychiatry, 66(2), 126–138. https://doi.org/10.1177/0706743720952251","article-title":null,"journal-title":"Canadian Journal of Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/s2468-2667(24)00299-8","key":"1614_CR37","year":"2025","issue":"2","author":"TM Yimer","volume":"10","first-page":"e148","unstructured":"Yimer, T. M., Hoch, E., Fischer, B., Dawson, D., & Hall, W. (2025). The adverse public health effects of non-medical cannabis legalisation in Canada and the USA. The Lancet Public Health, 10(2), e148–e159. https://doi.org/10.1016/s2468-2667(24)00299-8","article-title":null,"journal-title":"The Lancet Public Health","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1614"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["International Journal of Mental Health and Addiction"],"reference-count":37,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,23]]},"references-count":37,"short-container-title":["Int J Ment Health Addiction"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s11469-025-01614-y","is_oa":true,"title":"Frequent Non-medical Cannabis Use and Mental Health: A Cross-sectional Analysis Prior to Regulated Access","updated":"2025-12-24T00:55:44+00:00","published_date":"2025-12-23","best_oa_location":{"url":"https://doi.org/10.1007/s11469-025-01614-y","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1007/s11469-025-01614-y"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-14T18:30:49.575Z","tags":[{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"condition","value":"Anxiety Disorders","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"condition","value":"Depression","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"sample_size","value":"n=2207","value_numeric":2207},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"warning","value":"Cross-sectional baseline data; temporality and causality cannot be inferred.","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"warning","value":"Effect sizes for the mixed-model associations were not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1007/s11469-025-01614-y","tag_type":"warning","value":"Participants were entering a regulated cannabis access study in Zurich, which may limit generalizability to other settings or the general population.","value_numeric":null}],"summaries":{"what_studied":"Baseline cross-sectional data from the Züri Can observational study in Zurich: 2,207 participants completed assessments before purchasing cannabis; depression/anxiety were measured with PHQ-9/GAD-7 and substance use with CUDIT-R/AUDIT-C.","key_result":"Despite frequent cannabis use (56.4% ≥4 days/week) and 24.5% meeting criteria for cannabis use disorder, depression and anxiety prevalence were 2.8% and 1.7%, respectively, lower than in the general population. Mixed-models showed modest positive associations between cannabis use and depressive/anxiety symptoms, while alcohol, other illicit substances, prescription medication use, female gender, and lower income had similar or stronger positive associations.","practice_takeaway":"In frequent cannabis users entering a regulated access program, prioritize screening for substance use disorders; mood disorder prevalence was low despite modest symptom links. Embedding tools like CUDIT-R, AUDIT-C, PHQ-9, and GAD-7 within regulated frameworks can help identify risk."}}],"initialOffset":14,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Cannabis Use Disorder"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Cannabis Use Disorder"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Cannabis Use Disorder"}}}]]

Papers